Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep 10;12(9):2577.
doi: 10.3390/cancers12092577.

A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?

Simone Marnitz  1   2 , Till Walter  1   2 , Birgid Schömig-Markiefka  2   3 , Tobias Engler  4 , Stefan Kommoss  4 , Sara Yvonne Brucker  4
Affiliations

A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?

Simone Marnitz et al. Cancers (Basel). .

Abstract

Endometrial cancer has been histologically classified as either an estrogen-dependent cancer with a favorable outcome or an estrogen-independent cancer with a worse prognosis. These parameters, along with the clinical attributions, have been the basis for risk stratification. Recent molecular and histopathological findings have suggested a more complex approach to risk stratification. Findings from the Cancer Genome Atlas Research Network established four distinctive genomic groups: ultramutated, hypermutated, copy-number low and copy-number high prognostic subtypes. Subsequently, more molecular and histopathologic classifiers were evaluated for their prognostic and predictive value. The impact of molecular classification is evident and will be recognized by the upcoming WHO classification. Further research is needed to give rise to a new era of molecular-based endometrial carcinoma patient care.

Keywords: L1CAM; MMRd; POLE; adjuvant radiation; brachytherapy; endometrial cancer; molecular classification; risk classification; risk stratification; uterus carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Current recommendations on risk stratification and therapy based on classical clinical risk factors and five-year overall survival (modified from AGO S3-Guideline).
See this image and copyright information in PMC

References

    1. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983;15:10–17. doi: 10.1016/0090-8258(83)90111-7. - DOI - PubMed
    1. Benedetti Panici P., Basile S., Salerno M.G., Di Donato V., Marchetti C., Perniola G., Palagiano A., Perutelli A., Maneschi F., Lissoni A.A., et al. Secondary analyses from a randomized clinical trial: Age as the key prognostic factor in endometrial carcinoma. Am. J. Obstet. Gynecol. 2014;210:363.e1–363.e10. doi: 10.1016/j.ajog.2013.12.025. - DOI - PubMed
    1. Ureyen I., Karalok A., Turkmen O., Kimyon G., Akdas Y.R., Akyol A., Tasci T., Turan T. Factors predicting recurrence in patients with stage IA endometrioid endometrial cancer: What is the importance of LVSI? Arch. Gynecol. Obstet. 2019;301:737–744. doi: 10.1007/s00404-019-05418-z. - DOI - PubMed
    1. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., Pearlman A., Maiman M.A., Bell J.G., Gynecologic Oncology Group A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 2004;92:744–751. doi: 10.1016/j.ygyno.2003.11.048. - DOI - PubMed
    1. Colombo N., Creutzberg C., Amant F., Bosse T., Gonzalez-Martin A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int. J. Gynecol. Cancer. 2016;26 doi: 10.1097/IGC.0000000000000609. - DOI - PMC - PubMed

LinkOut - more resources